Abstract
A 27-year-old woman underwent living kidney transplantation from her mother. She received basiliximab, tacrolimus, mycophenolate mofetil (MMF), and a corticosteroid. Before transplantation, her complete blood count and white cell differential were normal. On about the 70th postoperative day (POD 70), her white blood cell (WBC) count began to decrease. On POD 113, her WBC count was 2800/μL. There was no evidence of viral infection, other systemic infection or malignancy. Drug-induced neutropenia, especially MMF-induced neutropenia, was suspected, and the dosage of MMF was reduced. However, the neutrophil count fell to 0/μL within 2 weeks. We further reduced the dosage of MMF and administered granulocyte-colony stimulating factor (G-CSF), which only temporarily increased the neutrophil count. Then, MMF was discontinued and switched to azathioprine, resulting in recovery of neutrophil count without subsequent rejection. MMF-induced neutropenia frequently occurs and should be monitored not only by WBC count but also by white cell differential count, since early discontinuation is the key to successful resolution of neutropenia. Switching from MMF to azathioprine or administration of G-CSF with or without MMF discontinuation might be options for treatment to avoid subsequent rejection.
Similar content being viewed by others
References
Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transpl. 1996;10:77.
Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006;355:1967.
Brum S, Nolasco F, Sousa J, Ferreira A, Possante M, Pinto JR, et al. Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil. Transpl Proc. 2008;40:752.
Rerolle JP, Szelag JC, Le Meur Y. Unexpected rate of severe leucopenia with the association of mycophenolate mofetil and valganciclovir in kidney transplant recipients. Nephrol Dial Transpl. 2007;22:671.
Chen IM, Chang HH, Hsu CP, Lai ST, Hsieh YC, Shih CC. Correlation between body mass index and leucopenia after administration of valganciclovir for cytomegalovirus infection in Chinese cardiac recipients. Circ J. 2007;71:968.
Zafrani L, Truffaut L, Kreis H, Etienne D, Rafat C, Lechaton S, et al. Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study. Am J Transpl. 2009;9:1816.
Mourad M, Malaise J, Chaib Eddour D, De Meyer M, Konig J, Schepers R, et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem. 2001;47:88.
Banerjee R, Halil O, Bain BJ, Cummins D, Banner NR. Neutrophil dysplasia caused by mycophenolate mofetil. Transplantation. 2000;70:1608.
Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002;62:1060.
Johnson HJ, Swan SK, Heim-Duthoy KL, Nicholls AJ, Tsina I, Tarnowski T. The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function. Clin Pharmacol Ther. 1998;63:512.
Nogueras F, Espinosa MD, Mansilla A, Torres JT, Cabrera MA, Martin-Vivaldi R. Mycophenolate mofetil-induced neutropenia in liver transplantation. Transpl Proc. 2005;37:1509.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Matsui, K., Shibagaki, Y., Sasaki, H. et al. Mycophenolate mofetil-induced agranulocytosis in a renal transplant recipient. Clin Exp Nephrol 14, 637–640 (2010). https://doi.org/10.1007/s10157-010-0323-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10157-010-0323-y